Wird geladen...
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
PURPOSE OF REVIEW: To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research. RECENT FINDINGS: Palbociclib, ribociclib, and abemaciclib are each approved in combination wit...
Gespeichert in:
| Veröffentlicht in: | Curr Oncol Rep |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6573012/ https://ncbi.nlm.nih.gov/pubmed/30806829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11912-019-0769-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|